000			01632 a2200397 4500
005			20250513132423.0
264		0	_c19980129
008			199801s 0 0 eng d
022			_a1042-8194
024	7		_a10.3109/10428199709059689 _2doi
040			_aNLM _beng _cNLM
100	1		_aO'Flaherty, E
245	0	0	_aViability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity. _h[electronic resource]
260			_bLeukemia & lymphoma _cOct 1997
300			_a343-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBlood Preservation
650	0	4	_aCell Count
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aCells, Cultured
650	0	4	_aCryopreservation
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aEpirubicin _xadministration & dosage
650	0	4	_aErythroid Precursor Cells _xdrug effects
650	0	4	_aGranulocyte Colony-Stimulating Factor _xadministration & dosage
650	0	4	_aHematopoietic Stem Cells _xdrug effects
650	0	4	_aHumans
650	0	4	_aLymphoma, Non-Hodgkin _xdrug therapy
650	0	4	_aPhlebotomy
700	1		_aCebon, J
700	1		_aGrigg, A P
773	0		_tLeukemia & lymphoma _gvol. 27 _gno. 3-4 _gp. 343-9
856	4	0	_uhttps://doi.org/10.3109/10428199709059689 _zAvailable from publisher's website
999			_c9371968 _d9371968